1.36
+0(+0.00%)
Currency In USD
| Previous Close | 1.36 |
| Open | 1.35 |
| Day High | 1.39 |
| Day Low | 1.34 |
| 52-Week High | 3.19 |
| 52-Week Low | 1.28 |
| Volume | 62,641 |
| Average Volume | 156,952 |
| Market Cap | 46.65M |
| PE | -1.48 |
| EPS | -0.92 |
| Moving Average 50 Days | 1.61 |
| Moving Average 200 Days | 1.75 |
| Change | 0 |
If you invested $1000 in Rafael Holdings, Inc. (RFL) since IPO date, it would be worth $277.55 as of September 29, 2025 at a share price of $1.36. Whereas If you bought $1000 worth of Rafael Holdings, Inc. (RFL) shares 5 years ago, it would be worth $83.08 as of September 29, 2025 at a share price of $1.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
GlobeNewswire Inc.
Sep 16, 2025 12:00 PM GMT
First data on treatment of NPC1 with Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients1 showed stabilization or improvement in CGI-S score Data presented at th
Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)
GlobeNewswire Inc.
Aug 27, 2025 12:00 PM GMT
NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs evaluating Trappsol® C
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
GlobeNewswire Inc.
Jun 18, 2025 11:00 AM GMT
Phase 3 TransportNPC study to continue based on the independent DMC review of safety and efficacy data at prespecified 48-week interim analysis Data on the investigational candidate Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin), indicates that i